WAM
ENGN icon

Wolverine Asset Management’s enGene Therapeutics ENGN Stock Holding History

Wolverine Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13K Buy
+2,964
New +$12.1K ﹤0.01% 1483
2025
Q3 		– Sell
-6,361
Closed -$23.2K – 1668
2025
Q2 		$23.2K Buy
+6,361
New +$23.9K ﹤0.01% 1297
2024
Q4 		– Sell
-5,574
Closed -$36.8K – 1668
2024
Q3 		$36.8K Buy
+5,574
New +$41.5K ﹤0.01% 1210

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Wolverine Asset Management's ENGN Position: Q2 2026 in Review

Wolverine Asset Management opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 2,964 shares worth $5.13K. The stake represents ﹤0.01% of the portfolio and ranks #1483 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in ENGN as recently as Q2 2025.

Wolverine Asset Management first reported a position in ENGN in Q3 2024 and has held it in 3 quarters since. The position peaked at $36.8K in Q3 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Wolverine Asset Management held 2,964 shares of enGene Therapeutics worth $5.13K as of Q2 2026.
  • enGene Therapeutics was a new Wolverine Asset Management position in Q2 2026.
  • enGene Therapeutics made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1483 holding.
  • Wolverine Asset Management first reported a position in enGene Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Wolverine Asset Management's enGene Therapeutics position peaked at $36.8K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.